Polycystic Kidney Disease - PowerPoint PPT Presentation


PPT – Polycystic Kidney Disease PowerPoint presentation | free to download - id: 7f50a1-NzM5Y


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Polycystic Kidney Disease


Polycystic Kidney Disease Definition 1. Hereditary disease characterized by cyst formation and massive kidney enlargement 2. Adult form of disorder is autosomal ... – PowerPoint PPT presentation

Number of Views:49
Avg rating:3.0/5.0
Slides: 61
Provided by: hyp96


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Polycystic Kidney Disease

Polycystic Kidney Disease
  • Definition
  • 1. Hereditary disease characterized by cyst
    formation and massive kidney enlargement
  • 2. Adult form of disorder is autosomal dominant
    polycystic kidney disease and accounts for 10 of
    persons in End Stage Renal Disease (ESRD)
  • Pathophysiology
  • 1. Renal cysts are fluid-filled sacs affecting
    nephrons cysts fill, enlarge, multiply thus
    compressing and obstructing kidney tissue renal
    parenchyma atrophies, becomes fibrotic
  • 2. Cysts occur elsewhere in body including liver,

Polycystic Kidney Disease
  • Manifestations
  • 1. Disease is slowly progressive symptoms
    develop in age 30 40s
  • 2. Common manifestations include
  • a. Flank pain
  • b. Microscopic or gross hematuria
  • c. Proteinuria
  • d. Polyuria and nocturia (impaired ability to
    concentrate urine)
  • e. UTI and renal calculi are common
  • f. Hypertension from disrupted renal vessels
  • g. Kidneys become palpable, enlarged, knobby
  • h. Symptoms of renal insufficiency and chronic
    renal failure by age of 50 60

Polycystic Kidney Disease
  • Collaborative Care Determine extent of
    polycystic kidney disease
  • Diagnostic tests
  • 1. Renal ultrasonography primary choice for
    diagnostic assesses kidney size, identifies and
    locates renal masses cysts, tumors, calculi
  • 2. Intravenous pyelography (IVP) evaluate
    structure and excretory function of kidneys,
    ureters, bladder
  • 3. CT scan of kidneys detects and differentiates
    renal masses

Polycystic Kidney Disease
  • Management
  • 1. Mainly supportive prevent further renal
    damage from UTI, nephrotoxic substances,
    obstruction, hypertension
  • 2. Fluid intake of 2000 2500 mL to prevent UTI,
  • 3. Control of hypertension with ACE inhibitors
    and other antihypertensive agents
  • 4. Eventually require dialysis or transplantation
    (typically good candidates)

Polycystic Kidney Disease
  • Nursing Care and Nursing Diagnoses
  • 1. Risk for Ineffective Coping address genetic
    counseling and screening for family members
  • 2. Excess Fluid Volume
  • 3. Anticipatory Grieving
  • 4. Knowledge Deficit of measures to preserve
    kidney function

Clients with Renal Failure
  • Definition
  • 1. Condition in which kidneys are unable to
    remove accumulated metabolites from blood leads
    to altered fluid, electrolyte and acid-base
  • 2. May be due to kidney (primary disorder) or
    resulting from another disease in another organ
    or systemic (secondary disorder)
  • 3. Classified as acute (abrupt onset and may be
    reversible) or chronic (develops slowly and
    insidiously with few symptoms until kidneys are
    severely damaged and unable to meet bodys
    excretory needs)
  • 4. Common and costly disease with people with End
    Stage Renal Disease requiring dialysis or
    transplant to live
  • 5. 5 year survival rate for clients on dialysis
    is 31.3

Clients with Renal Failure
  • Acute Renal Failure (ARF)
  • 1. Definition
  • a. Rapid decline in renal function with azotemia
    fluid and electrolyte imbalances
  • b. High mortality rate but is related to clients
    being seriously ill and aged
  • Risk Factors
  • a. Major surgery or trauma
  • b. Infection
  • c. Hemorrhage
  • d. Severe heart failure, liver disease
  • e. Lower urinary tract obstruction
  • f. Use of nephrotoxic contrast media and

Clients with Renal Failure
  • Pathophysiology involved with cause categories
  • a. Prerenal
  • 1. 55 60 cases of ARF
  • 2. Cause Conditions that affect renal blood flow
    and perfusion
  • A .Decrease vascular volume
  • B .Decrease cardiac output
  • C .Decrease vascular resistance
  • b. Intrarenal
  • 1. 35-40 cases of ARF
  • 2. Cause Acute damage to renal parenchyma and
  • a. Acute glomerulonephritis
  • b. Vascular disorders including vasculitis,
    malignant hypertension, arterial or venous

Clients with Renal Failure
  • c. Acute Tubular Necrosis (ATN) Destruction of
    tubular epithelial cell with abrupt decline in
    renal function from
  • 1. Prolonged ischemia (gt2 hours) as with surgery,
    severe hypovolemia, sepsis, trauma, burns
  • 2. Nephrotoxins
  • a. Aminoglycoside antibiotics
  • b. Radiologic contrast media
  • c. Other potential drugs NSAIDs, heavy metals,
    ethylene glycol (antifreeze)
  • 3. Nephrotoxins have increased risk with clients
    with preexisting renal insufficiency or state of
  • 4. Rhabdomyolysis excess myoglobin from skeletal
    muscle injury clogs renal tubules (muscle trauma,
    drug overdose, infection)
  • 5. Hemolysis red blood cell destruction

Clients with Renal Failure
  • Postrenal
  • 1. lt5 cases of ARF
  • 2. Cause Obstructive prevents urine excretion
  • a. Benign prostatic hypertrophy
  • b. Renal or urinary tract calculi or tumors

Clients with Renal Failure
  • Course and Manifestations of ARF in 3 phases
  • a. Initiation Phase
  • 1. Lasts hours to day
  • 2. Begins with initiating event ends when
    maintenance phase begins
  • 3. Good prognosis if treated at this phase
  • 4. Few manifestations identified when
    maintenance phase begins
  • b. Maintenance Phase
  • 1. Characterized by significant fall in GFR and
    tubular necrosis
  • 2. Oliguric or non-oliguric but kidneys not
    eliminating wastes, water, electrolytes, acids
    azotemia, fluid retention, electrolyte imbalances
    (hyperkalemia, hypocalcemia, hyperphosphatemia),
    acidosis (impaired hydrogen ion elimination)
  • 3. Anemia after several days due to suppressed
    erythropoetin secretion impaired immune function

Clients with Renal Failure
  • 4. Salt and water retention leading to
    hypertension and risk for heart failure and
    pulmonary edema
  • 5. Hyperkalemia cardiac dysrhythmias and EKG
    changes, muscle weakness, nausea, diarrhea
  • 6. Confusion, disorientation, agitation or
    lethargy, hyperreflexia, possible seizures, coma
  • 7. Vomiting, decreased or absent bowel sounds
  • c. Recovery Phase
  • 1. Progressive tubule cell repair and
    regeneration return of GFR to pre-ARF levels
  • 2. Diuresis occurs as kidney recover but BUN,
    Creatinine, potassium and phosphate remain high
  • 3. Renal function improves rapidly first 5 25
    days but improvement may continue for up to a

Clients with Renal Failure
  • Collaborative Care
  • a. Prevention of ARF is goal for all clients,
    especially those at high-risk
  • 1. Preserve kidney perfusion by adequate vascular
    volume, cardiac output and blood pressure
  • 2. Limiting use of nephrotoxic medications or
    using minimal effective dose, maintaining
    hydration, monitoring renal function tests
  • b. Treatment goals
  • 1. Identify and correct underlying cause
  • 2. Prevent additional renal damage
  • 3. Restore urine output and kidney function
  • 4. Compensate for impaired renal function
    maintain fluid and electrolyte balance

Clients with Renal Failure
  • Diagnostic tests to identify ARF
  • a. Urinalysis
  • 1. Fixed specific gravity 1.010 (low)
  • 2. Proteinuria, if glomerular damage
  • 3. Presence of red blood cells (glomerular
    dysfunction), white blood cells (inflammation),
    renal tubule epithelial cells (ATN)
  • 4. Cell casts (protein and cellular debris molded
    in shape of tubular lumen) brown color may
    indicate hemoglobinuria or myoglobinuria
  • b. Serum BUN and creatinine
  • 1. Creatinine rises rapidly (24 48 hours) and
    peaks in 5 10 days rise is slower if output
  • 2. Halt in rise of BUN and Creatinine signals
    onset of recovery

Clients with Renal Failure
  • Serum Electrolytes
  • 1. Monitored to determine whether to initiate
  • 2. Moderate rise in potassium
  • 3. Hyponatremia related to water excess
  • d. CBC showed moderate anemia and low hematocrit
    (Iron and folate may be low and add to anemia)
  • e. Renal ultrasound used to identify any
    obstruction, identify acute from chronic renal
  • f. CT scan identify obstruction and kidney size
  • g. IVP, retrograde pyelography, or antegrade
  • 1. Assess renal structure and function
  • 2. Retrograde and antegrade testing less toxicity
    from contrast media
  • h. Renal biopsy determine cause, differentiate
    acute from chronic

Clients with Renal Failure
  • Medications
  • a. Intravenous fluids and blood volume expanders
    to restore renal perfusion
  • b. Low dose Dopamine (Intropin) intravenous
    infusion to increase renal blood flow and improve
    cardiac output
  • c. Diuretic Furosemide (Lasix) or osmotic
    diuretic such as mannitol along with intravenous
    fluids washes out nephrons prevents oliguria
    reducing azotemia and electrolyte imbalance
  • d. Antihypertensive medications including ACE
    inhibitors to limit renal injury

Clients with Renal Failure
  • Medications to prevent possible complications
  • 1. Prevention of gastrointestinal bleeding (at
    risk due to stress, impaired platelet function)
  • a. Antacids
  • b. H2 receptor antagonists
  • c. Proton-pump inhibitors
  • 2. Hyperkalemia serum K gt 6.5 mEq/L puts client
    at risk for cardiac arrest
  • a. Calcium chlorides
  • b. Bicarbonate
  • c. Insulin and glucose

Clients with Renal Failure
  • d. Sodium polystyrene sulfonate (Kayexalete)
  • 1. Removes potassium from body primarily in large
  • 2. If given orally, is combined with sorbitol
  • 3. May be given as retention enema with tap water
    enema to follow after 30 60 minutes
  • 3. Hyperphosphatemia
  • a. Aluminum hydroxide (AlternaGEL, Amphojel,
  • b. Binds with phosphates in GI tract and is
    eliminated from bowel

Clients with Renal Failure
  • Fluid Management
  • a. Once vascular volume and renal perfusion
    restored, fluids are restricted
  • b. Often intake is calculated by adding output
    from previous 24 hours and 500 ml for insensible
  • c. Fluid balance monitored by daily weights and
    serum Na level

Clients with Renal Failure
  • Dietary Management
  • a. Renal insufficiency and underlying disease
    creates increased rate of catabolism (breakdown
    of body proteins) and decreased rate of anabolism
    (tissue repair)
  • b. Client needs adequate nutrition and calories
    to prevent catabolism but protein intake needs to
    be limited to minimize azotemia
  • c. Protein limited to 0.6g/kg body weight per
    day protein should be of high biologic value
    (contains essential amino acids)
  • d. Carbohydrate intake is increased for adequate
    calories and protein-sparing effect

Clients with Renal Failure
  • Dialysis
  • a. Dialysis is the diffusion of solute molecules
    across semipermeable membrane from area of higher
    solute concentration to lower concentration
  • b. Dialysis used to remove excess fluid, waste
    products from client with renal failure can
    rapidly remove nephrotoxins from blood

A hemodialysis system
Continuous arteriovenous hemofiltration (CAVH)
An arteriovenous fistula
An arteriovenous shunt in the forearm
Options for long-term vascular access for
Peritoneal dialysis
Manual peritoneal dialysis via an implanted
abdominal catheter (Tenckhoff catheter)
Clients with Renal Failure
  • Hemodialysis Dialysis process
  • a. In this type of dialysis, blood is taken from
    client via vascular access and pumped into a
    dialyzer blood is separated from the dialysate
    (dialysis solution) by semipermeable membrane
  • b. Processes of diffusion and ultrafiltration
    remove waste products, electrolytes, excess water
  • c. Glucose, electrolytes, water can pass through,
    but larger molecules (protein, red blood cells)
    are blocked
  • d. Substances can be added to dialysate to
    diffuse into the blood of the client
  • e. Client with ARF may undergo hemodialysis daily
    initially, then 3 4 times/week according to
    client condition 3 4 hours at a time

Clients with Renal Failure
  • Complications associated with hemodialysis
  • a. Hypotension, most common, related to changes
    in osmolality, rapid removal from vascular
    department, vasodilation
  • b. Bleeding related to platelet function and use
    of heparin during dialysis
  • c. Infection, local or systemic Staphylococcus
    aureus septicemia associated with infected
    vascular access site higher rates of hepatitis B
    and C, cytomegalovirus, HIV in hemodialysis

Clients with Renal Failure
  • 13. Continuous Renal Replacement Therapy (CRRT)
  • a. Technique used, which allows more gradual
    fluid and solute removal than hemodialysis used
    for clients with ARF unable to tolerate
  • b. Done over period of 12 hours or more
  • 14. Vascular Access for Hemodialysis
  • a. Acute or temporary access is gained inserting
    double lumen catheter into subclavian, jugular,
    or femerol vein
  • b. Blood is drawn from proximal portion of
    catheter and returned to circulation through
    distal end of catheter

Clients with Renal Failure
  • Arteriovenous (AV) fistula created for longer
    term access for dialysis
  • 1. Surgical anastomosis of artery and vein in
    non-dominant arm, usually radial artery and
    cephalic vein
  • 2. Usually cannot use fistula for hemodialysis
    access for a month while it matures
  • 3. Nurse or client can assess functional fistula
    for complications
  • a. Thrombosis (clotted off) check for palpable
    thrill, audible bruit
  • b. Infection check for redness, drainage
  • 4. Venipunctures and blood pressures should not
    be done in arm with the AV fistula
  • 5. AV fistulas are commonly used for vascular
    access for dialysis clients with chronic renal

Clients with Renal Failure
  • Peritoneal dialysis process involves
  • a. Peritoneal membrane of client is used as
    dialyzing surface
  • b. Warmed sterile dialysate instilled into
    peritoneal cavity through a catheter that has
    been inserted into peritoneal cavity
  • c. Metabolic waster products and excessive
    electrolytes diffuse into dialysate while it
    remains in abdomen
  • d. Water diffusion is controlled by glucose in
    the dialysate which acts as an osmotic agent
  • e. Fluid is drained off by gravity into sterile
    bag at set intervals, thus removing waste
    products and excess fluid

Clients with Renal Failure
  • Disadvantages of peritoneal dialysis
  • a. Dialysis is more gradual and may be slow for
  • b. Risk of peritonitis
  • c. Contraindicated for clients with abdominal
    surgery, peritonitis, significant lung disease
  • Health Promotion Prevention of ARF
  • a. Maintenance of fluid volume and cardiac output
  • b. Reduce risk of exposure to nephrotoxins
  • c. Report output lt 30 ml per hour in clients at
  • d. Report dehydration, monitor renal function
    tests in clients receiving nephrotoxic

Clients with Renal Failure
  • Nursing Diagnoses for clients in ARF
  • a. Excess Fluid Volume
  • b. Imbalanced Nutrition Less than body
  • c. Deficient Knowledge
  • Home care Client who is recovering from ARF
    will need teaching for prescribed diet and fluid
    intake, avoidance of nephrotoxins, prevention of
    infection, continue under medical supervision

Clients with Renal Failure
  • Client with Chronic Renal Failure (CRF)
  • Definition
  • a. Progressive renal tissue destruction and loss
    of function
  • b. May progress over many years without being
    recognized until kidneys are unable to excrete
    metabolic wastes and regulate fluid and
    electrolytes End-stage Renal Disease (ESRD)
  • c. Incidence is increasing especially in older
    adults higher in African Americans, Native
  • d. Conditions causing chronic renal failure
    diffuse bilateral disease of kidneys with
    progressive destruction and scarring diabetes is
    leading cause of ESRD then hypertension

Clients with Renal Failure
  • Pathophysiology and Manifestations of Stages
  • a. Decreased Renal Reserve Early Stage
  • 1. Unaffected nephrons compensate for lost
  • 2. GFR is about 50 of normal
  • 3. Client is asymptomatic
  • 4. BUN and serum creatinine are normal
  • b. Renal Insufficiency
  • 1. GRF falls to 20 50 of normal
  • 2. Azotemia and some manifestations
  • 3. Insult to kidneys could precipitate onset
    renal failure (infection, dehydration, exposure
    to nephrotoxins, urinary tract obstructions)

Clients with Renal Failure
  • c. Renal failure
  • 1. GRF lt 20 of normal
  • 2. BUN and serum creatinine rise sharply
  • 3. Oliguria, manifestations of uremia
  • d. End-stage renal disease (ESRD)
  • 1. GRF lt 5 of normal
  • 2. Renal replacement therapy necessary to sustain

Clients with Renal Failure
  • ESRD Uremia (urine in blood)
  • a. Early manifestations
  • 1. Nausea, apathy, weakness, fatigue
  • 2. Progresses to frequent vomiting, increasing
    weakness, lethargy, confusion
  • b. Fluid and electrolyte effects
  • 1. Urine less concentrated with proteinuria and
  • 2. Sodium and water retention
  • 3. Hyperkalemia (Muscle weakness, paresthesia,
    EKG changes)
  • 4. Hyperphosphatemia, hypocalcemia,
  • 5. Metabolic acidosis

Clients with Renal Failure
  • Cardiovascular effects
  • 1. Systemic hypertension
  • 2. Edema and heart failure pulmonary edema
  • 3. Pericarditis metabolic toxins irritate
    pericardial sac less often now with dialysis
  • 4. Cardiac tamponade fluid in pericardial sac
  • Hematologic effects
  • 1. Anemia contributing to fatigue, weakness,
    depression, impaired cognition, impaired cardiac
  • 2. Impaired platelet function
  • Immune system effects
  • 1. WBC declines
  • 2. Humoral and cell-mediated immunity impaired
  • 3. Fever suppressed

Clients with Renal Failure
  • Gastrointestinal effects
  • 1. Anorexia, nausea, vomiting, hiccups
  • 2. GI ulcerations, increased risk for GI bleeding
  • 3. Uremic fetor urinelike breath odor
  • Neurologic effects
  • 1. Changes in mentation, poor concentration
  • 2. Fatigue, insomnia
  • 3. Psychotic symptoms, seizures, coma
  • 4. Peripheral neuropathy restless leg
    syndrome, sensations of crawling, prickling
  • 5. Muscle weakness, decreased deep tendon
    reflexes, gait disturbances

Clients with Renal Failure
  • Musculoskeletal effects
  • 1. Renal osteodystrophy (renal rickets)
    characterized by osteomalacia (bone softening)
    and osteoporosis
  • 2. Bone tenderness and pain
  • Endocrine and metabolic effects
  • 1. Elevated uric acid levels risk for gout
  • 2. Resistance to insulin, glucose intolerance
  • 3. High triglyceride and lt HDL levels resulting
    in accelerated atherosclerotic process
  • 4. Menstrual irregularities reduced testosterone
  • Dermatologic effects
  • 1. Yellowish hue to skin
  • 2. Dry skin with poor turgor
  • 3. Pruritis due to metabolic wastes deposited in
  • 4. Uremic frost crystallized deposits of urea on

Clients with Renal Failure
  • Collaborative Care
  • a. Eliminate factors that further decrease renal
  • b. Maintenance of nutritional status with minimal
    toxic waste products
  • c. Identify and treat complications of CRF
  • d. Preparation for dialysis or renal

Clients with Renal Failure
  • Diagnostic Tests Identify CRF and monitor renal
    function by following levels of metabolic wastes
    and electrolytes
  • a. Urinalysis fixed specific gravity at 1.010
    excess protein, blood cells, cellular casts
  • b. Urine culture identify infection
  • c. BUN and serum creatinine evaluate kidney
  • 1. BUN levels
  • a. Mild azotemia 20 50 mg/dL
  • b. Severe renal impairment gt 100 mg/dL
  • c. Uremic symptoms gt 200mg/dL
  • 2. Creatinine levels gt4 mg/dL indicate serious
    renal impairment
  • d. Creatinine Clearance evaluates GFR and renal
  • 1. Decreased renal reserve 32.5 130 mL/min
  • 2. Renal insufficiency 10 30 mL/min
  • 3. ESRD 5 10 mL/min

Clients with Renal Failure
  • e. Serum electrolytes monitored throughout
    course of CRF
  • f. CBC moderately severe anemia with hematocrit
    20 30 low hemoglobin reduced RBCs and
  • g. Renal ultrasonography CRF decreased kidney
  • h. Kidney biopsy diagnose underlying disease
    process differentiate acute from chronic

Clients with Renal Failure
  • Medications
  • a. General effects of CRF on medication effects
  • 1. Increased half-life and plasma levels of meds
    excreted by kidneys
  • 2. Decreased drug absorption if phosphate-binding
    agents administered concurrently
  • 3. Low plasma protein levels can lead to toxicity
    when protein-bound drugs are given
  • 4. Avoid nephrotoxic meds or give with extreme
  • b. Diuretics (furosemide, other loop diuretics)
  • 1. Reduce edema
  • 2. Reduce blood pressure
  • 3. Lower potassium
  • c. Antihypertensive medications ACE inhibitors
  • d. Sodium bicarbonate or calcium carbonate
    correct mild acidosis
  • e. Oral phosphorus binding agents (calcium
    carbonate, calcium acetate) to lower phosphate
    levels and normalize calcium levels
  • f. Aluminum hydroxide for acute treatment of

Clients with Renal Failure
  • g. Vitamin D supplements to improve calcium
  • h. To treat dangerously high potassium levels
  • 1. Intravenous bicarbonate, insulin, glucose
  • 2. Sodium polystyrene sulfonate (Kayexalate)
  • i. Folic acid, iron supplements to combat anemia
  • j. Multiple vitamin supplement
  • Dietary and Fluid Management
  • a. Early in course of CRF diet modifications to
    slow kidney failure, uremic symptoms, and
  • b. Restrict proteins (40 gm/day) of high biologic
  • c. Increase carbohydrate intake (35kcal/kg/day)
  • d. Limit fluid to 1 2 L per day limit sodium
    to 2 g/day
  • e. Restrict potassium (60 -70 mEq/day) no salt
  • f. Restrict phosphorus foods (meat, eggs, dairy

Clients with Renal Failure
  • Renal Replacement Therapies considered when
    medications and dietary modifications are no
    longer effective
  • a. Hemodialysis establish vascular access
    (create AV fistula) months ahead
  • b. Peritoneal dialysis can be initiated when
    indicated training client and/or family involved
  • c. Transplantation tissue typing and
    identification of living related potential donors
    including health assessment of donor
  • Dialysis
  • a. Considerations
  • 1. Dialysis manages ESRD, but does not cure it
  • 2. Hemodialysis or peritoneal dialysis is
    constant factor of life
  • 3. Depending on individual client situation and
    total health, client may prefer death to dialysis

Clients with Renal Failure
  • Hemodialysis for ESRD
  • 1. Treatments are 3 times per week for 9 12
  • 2. Specific dialysis orders according to body
    size, residual renal function (based on that
    days current lab test results), dietary intake,
    concurrent illnesses
  • 3. Complications during treatment are hypotension
    and muscle cramps dialysis disequilibrium
  • 4. Long term complications are infection and
    vascular access problems
  • 5. Cardiovascular disease is leading cause of
    death for hemodialysis clients higher death rate
    than clients on peritoneal dialysis or

Clients with Renal Failure
  • Peritoneal Dialysis for ESRD
  • 1. Continuous ambulatory peritoneal dialysis
    (CAPD) most common
  • 2. 2 liters of dialysate instilled into
    peritoneal cavity and catheter sealed empty and
    replace every 4 6 hours
  • 3. Continuous cyclic peritoneal dialysis (CCPD)
    uses delivery device during nighttime hours and
    continuous dwell during day
  • Advantages over hemodialysis
  • a. Eliminates vascular access and heparinization
  • b. Avoids rapid fluctuation in extracellular
  • c. Diet intake is more liberal with fluids and
  • d. Regular insulin can be added to dialysate to
    manage hyperglycemia for diabetics
  • e. Client more able to self-manage

Clients with Renal Failure
  • Disadvantages of peritoneal dialysis
  • a. Less effective metabolite elimination
  • b. Risk for infection (peritonitis dialysate
    returns cloudy should be straw colored)
  • c. Serum triglyceride levels increase
  • d. Altered body image with peritoneal catheter

Clients with Renal Failure
  • Kidney Transplant
  • a. Background
  • 1. Treatment of choice for ESRD
  • 2. Primarily limited by availability of kidneys
  • 3. Many persons on waiting list for kidney
  • 4. Improves survival and quality of life for ESRD
  • b. Organ Donors
  • 1. Majority are from cadavers
  • 2. Transplants from living donors increasing
  • 3. Close match between blood and tissue type
    desired HLA are compared 6 in common is perfect
  • 4. Living donors must be in good physical health
    nephrectomy is major surgery and remaining kidney
    must be healthy

Placement of a transplanted kidney.
Placement of a transplanted kidney in the right
iliac fossa
Clients with Renal Failure
  • Cadaver donors
  • 1. Cadaver kidney from persons who
  • a. Meets criteria for brain death
  • b. Are aged lt 65 years old
  • c. Are free of systemic disease, malignancy, or
    infection including HIV, hepatitis B, C
  • 2. Kidney removed and preserved by hypothermia
  • a. Transplant in 24 48 hours
  • b. Use technique continuous hypothermic
    pulsatile perfusion, and transplant up to 3 days
  • 3. Donor kidney placed in lower abdominal cavity,
    renal artery, vein, and ureter are anastomosed

Clients with Renal Failure
  • Immunosuppressive therapy
  • 1. Necessary to block immune response that would
    reject transplanted organ
  • 2. Medications include
  • a. Glucocorticoids prednisone and
    methylprednisolone used for maintenance and
    treatment of acute rejection episodes
  • b. Azathioprine inhibits cellular and humoral
    immunity metabolized by liver
  • c. Mycophenolate mofetil more potent and minimal
    bone marrow suppression
  • d. Cyclosporine affects cellular immunity is
    hepatotoxic and nephrotoxic

Clients with Renal Failure
  • Rejection
  • 1. Can occur at any time
  • 2. Acute rejection
  • a. Occurs within months of transplant
  • b. Cellular immune response with T cells
  • c. Few manifestations
  • 1. Rise in serum creatinine
  • 2. Possibly oliguria
  • d. Treatment
  • 1. Methylprednisolone
  • 2. OKT3 monoclonal antibody
  • 3. Chronic rejection
  • a. Develops months to years post transplant
  • b. Major cause of graft loss
  • c. Involves both humoral and cellular immune
  • d. Manifestations (same as renal failure)
  • 1. Progressive azotemia
  • 2. Proteinuria
  • 3. Hypertension

Clients with Renal Failure
  • Complications of kidney transplant
  • 1. Hypertension
  • 2. Glomerular lesions with manifestations of
  • 3. Increased risk for myocardial infarction and
  • Complications associated with long-term
  • 1. Infection bacterial, viral, fungal in blood,
    lung, CNS
  • 2. Tumors carcinoma in situ in cervix,
    lymphomas, skin cancers
  • 3. Steroid use leads to bone problems, peptic
    ulcer disease, cataract formation

Clients with Renal Failure
  • Health Promotion
  • a. Ensure all clients with impaired renal
    function are well hydrated, especially while
    receiving nephrotoxic drugs
  • b. Encourage clients with ESRD to explore
    transplant options
  • Nursing Diagnoses
  • a. Impaired Tissue Perfusion renal
  • b. Imbalanced Nutrition Less than body
  • c. Risk for Infection
  • d. Disturbed Body Image

Clients with Renal Failure
  • Home Care
  • a. CRF and ESRD are long-term processes requiring
    client management
  • b. Extensive teaching required
  • 1. Monitoring health status
  • 2. Compliance with fluid and dietary restriction
    and medications
  • 3. Care involved with hemodialysis, peritoneal
    dialysis, or living with transplant
About PowerShow.com